WO2006035280A1 - Antagonistes des recepteurs muscariniques - Google Patents

Antagonistes des recepteurs muscariniques Download PDF

Info

Publication number
WO2006035280A1
WO2006035280A1 PCT/IB2005/002831 IB2005002831W WO2006035280A1 WO 2006035280 A1 WO2006035280 A1 WO 2006035280A1 IB 2005002831 W IB2005002831 W IB 2005002831W WO 2006035280 A1 WO2006035280 A1 WO 2006035280A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
alkyl
cycloalkyl
alkenyl
Prior art date
Application number
PCT/IB2005/002831
Other languages
English (en)
Other versions
WO2006035280A8 (fr
Inventor
Mohammad Salman
Anita Mehta
Naresh Kumar
Kirandeep Kaur
Arundutt Viswanatham Silamkoti
Bruhaspathy Miriyala
Shelley Aeron
Anita Chugh
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2006035280A1 publication Critical patent/WO2006035280A1/fr
Publication of WO2006035280A8 publication Critical patent/WO2006035280A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines

Abstract

La présente invention concerne, de manière générale, des antagonistes des récepteurs muscariniques de formule (I), lesquels sont utiles, entre autres, pour le traitement de diverses maladies des systèmes respiratoire, urinaire et gastro-intestinal médiées par des récepteurs muscariniques. L'invention concerne également le procédé de préparation des composés selon l'invention, des compositions pharmaceutiques contenant lesdits composés, ainsi que les méthodes de traitement de maladies médiées par des récepteurs muscariniques. Dans la formule (I), On représente un cycle contenant de l'azote présentant entre 5 et 9 atomes de carbone et T représente un groupe de pontage sélectionné dans le groupe comprenant (CH2)n-, -CH(Q)CH2-, -CH2CH(Q)CH2-, -CH2-O-CH2- ou -CH2-NH-CH2-), n est un entier sélectionné compris entre 0 et 3 (lorsque n est égal à zéro, alors T représente une liaison directe) ; Y représente alkylène, alcénylène, alkynylène ou aucun atome ; X représente NH ou oxygène.
PCT/IB2005/002831 2004-09-27 2005-09-26 Antagonistes des recepteurs muscariniques WO2006035280A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1846/DEL/2004 2004-09-27
IN1846DE2004 2004-09-27

Publications (2)

Publication Number Publication Date
WO2006035280A1 true WO2006035280A1 (fr) 2006-04-06
WO2006035280A8 WO2006035280A8 (fr) 2006-06-08

Family

ID=35589277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002831 WO2006035280A1 (fr) 2004-09-27 2005-09-26 Antagonistes des recepteurs muscariniques

Country Status (1)

Country Link
WO (1) WO2006035280A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2420237A1 (fr) 2010-08-11 2012-02-22 Ville Takio Dérivés fluorés d'isoquinoléines endogènes pour leur utilisation dans le traitement de maladies liées aux passages d'isoquinoline endogène
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
WO2019152809A1 (fr) 2018-02-02 2019-08-08 Vanderbilt University Antagonistes du récepteur muscarinique de l'acétylcholine m4
WO2020252222A1 (fr) * 2019-06-12 2020-12-17 Arkuda Therapeutics Modulateurs de la progranuline et leurs procédés d'utilisation
US11299481B2 (en) 2017-10-20 2022-04-12 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US11352344B2 (en) 2017-10-31 2022-06-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP0801067A1 (fr) * 1994-12-28 1997-10-15 Yamanouchi Pharmaceutical Co. Ltd. Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
WO2004018422A1 (fr) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
WO2004039801A1 (fr) * 2002-10-29 2004-05-13 Pharmacia & Upjohn Company Llc Derives de quinuclidinium en tant qu'agents antimuscariniques
WO2004056811A1 (fr) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Derives de flavaxate comme antagonistes de recepteurs muscariniques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP0801067A1 (fr) * 1994-12-28 1997-10-15 Yamanouchi Pharmaceutical Co. Ltd. Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
WO2004018422A1 (fr) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
WO2004039801A1 (fr) * 2002-10-29 2004-05-13 Pharmacia & Upjohn Company Llc Derives de quinuclidinium en tant qu'agents antimuscariniques
WO2004056811A1 (fr) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Derives de flavaxate comme antagonistes de recepteurs muscariniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199550, Derwent World Patents Index; Class B02, AN 1995-385649, XP002364183 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
EP2420237A1 (fr) 2010-08-11 2012-02-22 Ville Takio Dérivés fluorés d'isoquinoléines endogènes pour leur utilisation dans le traitement de maladies liées aux passages d'isoquinoline endogène
US11299481B2 (en) 2017-10-20 2022-04-12 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US11820757B2 (en) 2017-10-20 2023-11-21 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US11352344B2 (en) 2017-10-31 2022-06-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2019152809A1 (fr) 2018-02-02 2019-08-08 Vanderbilt University Antagonistes du récepteur muscarinique de l'acétylcholine m4
JP2021513519A (ja) * 2018-02-02 2021-05-27 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3746421A4 (fr) * 2018-02-02 2021-10-27 Vanderbilt University Antagonistes du récepteur muscarinique de l'acétylcholine m4
US11414406B2 (en) 2018-02-02 2022-08-16 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2020252222A1 (fr) * 2019-06-12 2020-12-17 Arkuda Therapeutics Modulateurs de la progranuline et leurs procédés d'utilisation
CN113950477A (zh) * 2019-06-12 2022-01-18 阿库达医疗公司 颗粒体蛋白前体调节剂和其使用方法

Also Published As

Publication number Publication date
WO2006035280A8 (fr) 2006-06-08

Similar Documents

Publication Publication Date Title
EP1797040A1 (fr) Antagonistes de recepteurs muscariniques
US7399779B2 (en) 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
US20090176856A1 (en) Muscarinic receptor antagonists
WO2006016245A1 (fr) Antagonistes des récepteurs muscariniques
WO2003091220A1 (fr) Antagonistes muscariniques
NZ230068A (en) Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
EP1828174A1 (fr) Antagonistes azabicycliques des recepteurs muscariniques
WO2006035280A1 (fr) Antagonistes des recepteurs muscariniques
US7446123B2 (en) Azabicyclo derivatives as muscarinic receptor antagonists
US7488748B2 (en) 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1781607A2 (fr) Derives de pyrrolidine utilises en tant qu'antagonistes des recepteurs muscariniques
US20070010568A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003214535B2 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2007007282A2 (fr) Antagonistes des recepteurs muscariniques
EP1590345A1 (fr) Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques
US7560479B2 (en) 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006005980A1 (fr) Derives de xanthine utilises en tant qu'antagonistes du recepteur muscarinique
KR20050023401A (ko) 무스카린 수용체 길항제로서 사용가능한 3,6-이치환된아자비시클로 [3.1.0]헥산 유도체

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase